首页> 外文期刊>Clinical immunology: The official journal of the Clinical Immunology Society >Corrigendum to 'Intratumoral FOXP3+VEGFR2+ regulatory T cells are predictive markers for recurrence and survival in patients with colorectal cancer' [Clin. Immunol. 146 (2013) 26-33]
【24h】

Corrigendum to 'Intratumoral FOXP3+VEGFR2+ regulatory T cells are predictive markers for recurrence and survival in patients with colorectal cancer' [Clin. Immunol. 146 (2013) 26-33]

机译:“肿瘤内FOXP3 + VEGFR2 +调节性T细胞是结直肠癌患者复发和生存的预测标志物”的更正[Clin。Phys.Lett。免疫146(2013)26-33]

获取原文
获取原文并翻译 | 示例
           

摘要

The authors regret that in the Abstract of the article referenced above the statement "Relatively low number of itFOXP3+VEGFR2+ cells significantly correlated with poor disease-free survival (DS) and overall survival (OS)" has an error that makes it inconsistent with the results reported in Fig. 4C and D. The word "poor" should be replaced by "better" so that the correct statement is "Relatively low number of itFOXP3+VEGFR2+ cells significantly correlated with better disease-free survival (DS) and overall survival (OS)."The authors would like to apologise for any inconvenience caused.
机译:作者感到遗憾的是,在以上引用的文章的摘要中,“与较低的无病生存期(DS)和总体生存期(OS)显着相关的itFOXP3 + VEGFR2 +细胞的数量相对较低”的陈述使该陈述与错误的陈述相矛盾。结果报告在图4C和D中。应将“差”一词替换为“更好”,以便正确的说法是“ itFOXP3 + VEGFR2 +细胞的数量相对较低,这与更好的无病生存率(DS)和总体生存率显着相关(OS)。“对于由此带来的任何不便,作者深表歉意。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号